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Background: Treatment of patients with recurrent glioma includes neurosurgical resection, chemotherapy, or
radiation therapy. In most cases, a full course of radiotherapy has been applied after primary diagnosis, therefore
application of re-irradiation has to be applied cauteously. With modern precision photon techniques such as
fractionated stereotactic radiotherapy (FSRT), a second course of radiotherapy is safe and effective and leads to
survival times of 22, 16 and 8 months for recurrent WHO grade II, III and IV gliomas.
Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose
deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in
comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calcu-
lated between 2 and 5 depending on the GBM cell line as well as the endpoint analyzed. Protons, however, offer
an RBE which is comparable to photons.
First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of primary high-grade glio-
mas showed promising results in a small and heterogeneous patient collective.
Methods Design: In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared to
FSRT applied to the area of contrast enhancement representing high-grade tumor areas in patients with recurrent
gliomas. Within the Phase I Part of the trial, the Recommended Dose (RD) of carbon ion radiotherapy will be
determined in a dose escalation scheme. In the subsequent randomized Phase II part, the RD will be evaluated in
the experimental arm, compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy.
Primary endpoint of the Phase I part is toxicity. Primary endpoint of the randomized part II is survival after re-
irradiation at 12 months, secondary endpoint is progression-free survival.
Discussion: The Cinderella trial is the first study to evaluate carbon ion radiotherapy for recurrent gliomas, and to
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Recurrent gliomas remain a major challenge in radiation
oncology. In the past, second courses of radiotherapy
have only been applied reluctantly, in fear of treatment-
related side effects. However, modern radiation techni-
ques have enabled the radiation oncologist to deliver
high local doses as an effective salvage treatment with
low rates of side effects.
Especially for GBM, with unsatisfactory outcomes
even after extensive research over the past centuries,
effective treatment at tumor recurrence are needed
urgently. With surgery and supportive care alone, overall
survival is about 3-5 months. Postoperative RT can
increase overall survival to 9-12 months [1]. A number
of studies have shown that an additional treatment with
chemotherapy can increase overall survival. This benefit,
however, is commonly associated with a high risk of
treatment-related side effects, especially with combina-
tion treatments, such as PCV, and with BCNU. Only
recently, significant increase in overall survival could be
achieved by adding TMZ, an orally applicable alkylating
substance, to postoperative radiotherapy. In a prospec-
tive randomized Phase III study performed by the
EORTC radiochemotherapy with TMZ was compared to
postoperative radiation alone. Overall survival could be
increased from 12.1 months to 14.6 months, with accep-
table toxicity. TMZ was applied in a dose of 75 mg/m
2/
die during radiotherapy, followed by 6 cycles of adjuvant
TMZ [2]. Therefore, standard treatment of patients with
GBM is currently considered to be postoperative radio-
chemotherapy with TMZ, followed by 6 cycles or adju-
vant TMZ.
However, with an overall survival of about 15 months,
treatment outcome still remains insufficient, and
patients develop tumor recurrences soon after primary
diagnosis.
For anaplastic gliomas, overall survival after standard
treatment following primary diagnosis, including neuro-
surgical resection and postoperative radiotherapy, lies
between 18 and 50 months [3]. However, also these
patients develop tumor recurrences after primary diag-
nosis, and effective salvage treatments are required.
Treatment of low grade gliomas has been discussed
controversially over the last years with respect to opti-
mal radiation dose and time point of radiotherapy. It
has been shown, that doses of 45-54 Gy are sufficient
for long-term local tumor control, and that early appli-
cation of radiotherapy can increase progression-free sur-
vival significantly, without altering overall survival as
compared to treatment applied for tumor progression
[4]. During follow-up, patients develop not only low
grade tumor progression, but also high-grade malignant
tumor lesions.
In the past, a second course of radiotherapy has been
applied reluctantly with conventional techniques as
treatment outcome outweighs the risk of treatment-
related side effects [5]. With modern high-precision
stereotactic photon techniques, such as Fractionated
Stereotactic Radiotherapy (FSRT) re-irradiation could be
established as a safe and effective treatment option for
recurrent gliomas [6]. Survival times of 111, 50 and 21
months for WHO Grade II, III and IV gliomas could be
shown with FSRT, with very low rates of side effects.
However, outcome still remains unsatisfactory [7].
Charged particles provide the physical advantage of
an inverted dose profile which enables steep dose gra-
dients. Neighboring organs at risk and surrounding
normal tissue can be spared from radiation doses.
Additionally, heavy charged particles, such as carbon
ions, as high-LET beams, are characterized by an
enhanced RBE. For glioblastoma cell lines, RBE values
between 2 and 5 have been reported depending on cell
l i n ea n de n d p o i n t[ 8 , 9 ] .
In general, GBM are treatment-resistant tumors. Early
studies using a high-dose proton boost could show that
total doses up to 90 Gy E were effective in preventing
local tumor recurrences, however, such high doses were
associated with high rates of side effects [10]. Therefore,
in general, standard radiation therapy is applied up to a
total dose of 60 Gy. Besides the physical advantages of
high local dose deposition provided by protons, carbon
ions are a promising treatment alternative due to their
biological benefits. A clinical study performed by the
National Institute of Radiological Sciences (NIRS) treated
48 patients with malignant gliomas with a carbon ion
boost up to total doses of 24.8 Gy E, of which 32 were
GBM [11]. In this study, no treatment related toxicity
exceeding CTCAE Grade II or higher were observed.
Therefore, the concept of a carbon ion radiotherapy for
the treatment of recurrent gliomas with contrast enhan-
cing lesions is a promising treatment alternative.
Carbon ion radiotherapy was available by the Depart-
ment of Radiation Oncology at the Gesellschaft für
Schwerionenforschung (GSI) in Darmstadt since 1997.
Superior treatment results for a number of tumor enti-
ties, such as chordomas and chondrosarcomas of the
skull base, as well as ACC have been shown, and carbon
ion radiotherapy is currently performed in the clinical
routine for these patients [12,13]. Safety of carbon ion
radiotherapy with respect to critical organs at risk, such
as the brain, brainstem or spinal chord, have been
shown in these studies. At the Heidelberg Ion Therapy
Center (HIT), treatment of over 1300 patients per year
with Proton and Carbon ion RT is possible.
In vitro data for the treatment of GBM with carbon
ions have shown superior effectivity compared to
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carbon ion RT for GBM; additionally a combination of
carbon ion radiotherapy and TMZ have been evaluated
and show an additive effect in GBM-cell lines [8]. A
first clinical study evaluating a carbon ion boost in
patients with GBM was recently published by Mizoe
et al. [15]. Median overall survival in patients with glio-
blastoma was 17 months; however, only small patient
numbers were evaluated and standard chemotherapy
with TMZ was not applied. In that study, the carbon
ion boost was applied with increasing total doses up to
24.8 Gy E. While toxicity was low even in the high dose
arm, the data showed that patients seem to benefit from
the high dose carbon ion boost.
The promising results in primary GBM and the
known physical and biological properties of carbon ion
offer a promising treatment alternative that should be
evaluated for the treatment of patients with recurrent
gliomas.
In the present CINDERELLA trial, the impact of car-
bon ion radiotherapy using intensity modulated raster-
scanning will be compared to FSRT which is considered
the treatment standard alternative for patients with
recurrent gliomas. In a first Phase I design, the RD of
carbon ion radiotherapy for re-irradiation of gliomas
will be determined. In the following Phase II part, the
RD of carbon ions will be compared to standard photon
radiotherapy delivered as FSRT,
Methods and Design
Study design
The trial will be performed as a single-center two-armed
randomized Phase I/II study.
Phase I: Dose Escalation
Patients fulfilling the inclusion criteria will be treated
with increasing total doses of carbon ion radiotherapy to
RD of carbon ion radiotherapy for re-irradiation of
recurrent gliomas.
Patients will be treated within seven increasing dose
regimens starting at 10 × 3 GyE up to 16 × 3 GyE.
Phase II: Randomized Part
Patients fulfilling the inclusion criteria will be rando-
mized into two arms:
Arm A - Experimental Arm
Carbon Ion Radiation Therapy
The total dose applied will be the RD determined in
the Phase I part of the study protocol.
Arm B - Standard Arm
Fractionated Stereotactic Radiotherapy with Photons
Total Dose 36 Gy, 18 fractions, 2 Gy single dose
A flow chart of the study is shown in Fig. 1.
Study objectives
The purpose of the trial is to compare carbon ion
radiotherapy to FSRT for the treatment of recurrent
gliomas delivered to the area of contrast-enhancement
in T1-weighted MRI and/or Amino-Acid-PET-positive
lesions.
In the Phase I study, the RD of carbon ion radiother-
apy will be determined in a dose escalation scheme. The
primary endpoint is toxicity.
In the randomized Phase II part of the study, carbon
ion radiotherapy treated at the recommended dose
evaluated in the phase I part will be compared to stan-
dard photon radiotherapy delivered as FSRT. The pri-




The primary objective is any Grade IV toxicity related to
the study treatment according to CTCAE Grade IV.
Figure 1 Flow Chart of the Cinderella-Study.
Combs et al. BMC Cancer 2010, 10:533
http://www.biomedcentral.com/1471-2407/10/533
Page 3 of 8Phase II




The secondary objective in the Phase I part is survival
after re-irradiation
Phase II
The secondary objectives of the study are progression-
free survival, toxicity and safety.
Patient selection: Inclusion criteria
Patients meeting all of the following criteria will be con-
sidered for admission to the trial:
- unifocal, supratentorial recurrent glioma (primary
histologies including any WHO Grade II or III
glioma or glioblastoma)
- prior course of standard photon radiotherapy
- contrast enhancement on T1-weighted MRI and/or
Amino-Acid-PET-positive high-grade tumor areas
- indication re-irradiation
- age ≥ 18 years of age
- Karnofsky Performance Score ≥60
- For women with childbearing potential, (and men)
adequate contraception.
- Ability of subject to understand character and indi-
vidual consequences of the clinical trial
- Written informed consent (must be available
before enrolment in the trial)
Patient selection: Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
- Multifocal Glioma or Gliomatosis cerebri
- refusal of the patients to take part in the study
- previous re-irradiation or prior radiosurgery or
prior treatment with interstitial radioactive seeds
- time interval of < 6 months after primary
radiotherapy
- Patients who have not yet recovered from acute
toxicities of prior therapies
- Known carcinoma < 5 years ago (excluding Carci-
noma in situ of the cervix, basal cell carcinoma,
squamous cell carcinoma of the skin) requiring
immediate treatment interfering with study therapy
- Pregnant or lactating women
- Participation in another clinical study or observa-
tion period of competing trials, respectively.
Treatment Assignment
Radiation therapy according to the protocol will be per-
formed in patients included into the study and after
assignment of the patients to the treatment arms after
randomization.
Patients withdrawn from the trial retain their identifi-
cation codes (e.g. randomization number, if already
given). New patients must always be allotted a new
identification code.
Treatment Planning
For FSRT and particle therapy, patients will be immobi-
lized using an individually manufactured head mask. For
treatment planning, contrast-enhanced CT as well as
MR-imaging will be performed for optimal target
definition.
Treatment planning for carbon ion and FSRT is to be
performed about 1-2 weeks prior to the start of re-
irradiation.
Organs at risk such as the brain stem, optic nerves,
chiasm and spinal chord will be contoured. Dose con-
straints of normal tissue will be respected according to
Emami et al. [16].
The Treatment Volume for Re-Irradiation will be
defined as the area of contrast enhancement on T1-
weighted MR-imaging adding a safety margin of 5 mm.
Amino-Acid-PET or SPECT-Examinations may be
used in addition to contrast-enhanced MRI for target
volume definition but are not mandatory.
FSRT planning is performed using standard photon-
treatment planning systems such as HELAX, Masterplan
or STP.
Carbon ion RT planning is performed using the treat-
ment planning software PT-Planning (Siemens, Erlan-
gen, Germany) including biologic plan optimization.
Biologically effective dose distributions will be calculated
using the a/b ratio for gliomas as well as for the end-
point late toxicity to the brain.
No interruptions > 4 days during study treatment
(carbon ion radiotherapy or FSRT) are allowed.
Patient positioning prior to FSRT or particle therapy
will be evaluated by comparison of x-rays to the DRRs.
Set up deviations >3 mm are corrected prior to
radiotherapy.
Dose Prescription Experimental (Carbon) Arm
The intensity-controlled rasterscan system will be used
for beam application. In the Phase I Dose Escalation
Part, increasing doses of carbon ion radiotherapy will be
evaluated in 7 steps starting at 10 × 3 Gy E up to 16 ×
3 Gy E. In this part, the RD of carbon ion radiotherapy
for re-irradiation of gliomas will be determined.
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domized phase II part of the study. The total dose will be
prescribed to the maximum of the calculated dose distri-
bution for the target volume. Treatment planning aims in
the coverage of the target volume by the 90%-isodose line.
Dose specification is based on biologic equivalent dose
because of the high RBE of carbon ions, which differs
throughout the target volume due to its dependence on
various factors. RBE will be calculated at each voxel
throughout the target volumes and biological optimiza-
tion will be performed. The dose prescription used is
related to the isoeffective dose GyE using daily fractions
of 2 Gy and a weekly fractionation of 5 × 3 Gy.
A typical treatment plan is shown in Fig. 2.
Dose Prescription Standard (Photon) Arm
Eighteen fractions of a single dose of 2 Gy up to a total
dose of 36 Gy will be prescribed to the isocenter. Treat-
ment planning aims in the coverage of the target
volume by the 90%-isodose line.
Statistical calculations for trial sample size
The statistical methods applied for this study are subject
to GCP guidelines (Guidelines of the International Con-
ference on Harmonisation (ICH) e.g.
￿ ICH E3: Structure and Contents of Clinical Study
Reports,
￿ ICH E6: Good Clinical Practice (GCP). Consoli-
dated Guideline,
￿ ICH E9: Note for Guidance on Statistical Principles
in Clinical Trials) and will be performed in accor-
dance with CESAR SOP 8 (Statistical Analysis/Bio-




Phase I part of this study is conducted to choose the
Recommended Dose (RD) of carbon ion radiotherapy
for the phase II part between seven dose levels based on
the dose escalation scheme.
Phase II
The phase II part of this study is designed to demon-
strate superiority in survival of carbon ion radiotherapy
(experimental) to FSRT (standard) in patients with
recurrent or progressive gliomas. The primary endpoints
variable is overall survival time after at least 12 months
of follow-up (OS_12m) defined as time to death for any
reason during the follow-up period of at least 12 months
starting from date of randomization.
Figure 2 Typical treatment plan for carbon ion radiotherapy for a patients with a recurrent glioblatoma. Treatment is performed using
the Siemens TPS for particle therapy, target volume delienation is based on CT- and MR-imaging with contrast enhancement.
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Phase I
Seven DLs are included in the dose finding part. It is
assumed that the probability of a DLT is 1/3. With n =
8 patients in each DL, the power that at each DL at
least one DLT is observed is greater than 95%. There-
fore a maximum of 56 patients will be treated in the
phase I part of this study.
Within this study, DLTs are defined as any grade IV
toxicity according to CTCAE Version 4.0 associated to
study treatment.
Phase II
￿ The size of the phase II part of this study is deter-
mined by the primary aim of testing experimental
treatment for superiority over standard treatment.
This endpoint is a censored failure time.
￿ Information on the OSB_12mR (overall survival
rate after 12 months of follow-up for standard treat-
ment) is given in literature data [17].
To calculate survival data, a population distribution of
GBM in 34.3%, Grade III Tumors in 24.4% and low
grade gliomas in 41.3% was used [17]. Survival rates for
overall survival were taken as published previously with
23% for GBM 65% for Grade III, and 77% for low-grade
gliomas observed at 12 months after re-irradiation [17].
Overall OSB_12mR can be calculated as weighted
mean rate. Therefore OSB_12mR is expected to be 56%.
The study will be designed to detect an improvement in
OS_12mR of 10% (OSA_12mR = 66%).
The statistical error rates for this test of superiority
are set as a =0 . 0 5a n db = 0.20 (power 80%). Sample
size calculation is based on an unstratified log-rank. It
can be expected that including histology in a stratified
log-rank test will increase the power as compared to the
unstratified test.
The recruitment period will be 36 months with a
minimal follow-up time of 12 months. In order to put
more patients on the experimental treatment, an unba-
lanced randomization allocation ratio of 2:3 was chosen.
For this set of assumptions, the sample size calculation
programme PASS 2008 yields the total sample size for
standard treatment of n = 138 and n = 207 for experi-
mental treatment. Allowing for failures for various rea-
sons of 10%, a total of N = 380 is required for this part
of the study (n = 152 in standard arm and n = 228 in




Primary endpoint Safety will be assessed by the type,
incidence and severity (graded by the NCI CTC-AE Ver-
sion 4.0) and relation to treatment. All patients treated at
least once with one of the seven dose levels defined above
will be described individually and summarized by dose
level. No confirmatory statistical analysis will be performed.
Secondary endpoint
Descriptive summary tables will be presented on base-
line patient characteristics as well as for all safety para-
meters by dose level. Patients will be monitored for
adverse events using NCI-CTC version 4.0.
Phase II
Primary endpoint The primary endpoint variable
OS_12 m was planned to be analysed by a one sided
logrank test of stratified by histology testing H0:O S A-12
m=O S B-12 m versus H1:O S A-12 m > OSB-12 m at the
level of alpha = 5%. One interim analysis is planned
when 50% of the number of expected events under the
null-hypothesis have occurred. In order to preserve the
significance level of 5% a sequential plan with alpha-
spending of De-Mets and Lan with limits of O’Brien
and Fleming is applied.
Overall survival will be summarized by Kaplan-Meier
curves. Median estimates as well as associated 95% con-
fidence intervals will be reported. Further, a descriptive
analysis of the primary outcome variable is performed
applying a Cox-regression model.
Secondary endpoints
￿ Progression-free survival will be analyzed analo-
gously to the primary endpoints. P-value of the log-
rank test and test within the Cox regression will be
interpreted descriptively.
￿ Safety/Toxicity will be assessed by the type, inci-
dence, severity (graded by the NCT CTCAE Version
4.0), and relatedness of AEs to treatment and by
assessment of laboratory parameters related to
safety. Tolerability and dosing will be described by
numbers of patients in whom treatment was given
as planned, delayed or permanently stopped. All ana-
lyses will be performed separately for both treatment
groups.
A detailed SAP will be designed after initiating the
study and before start of data analysis by the biometric
center. It will consider all analyses necessary to charac-




Besides the planned analysis during and after phase I
part, no further interim analysis are planned.
Phase II
For the primary aim and the primary endpoint of the
phase II, one interim analysis will be performed when
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have occurred. Under the study hypotheses, 114 events
will be occurred under the null hypothesis approxi-
mately after 26 months after start of recruitment.
Using O’Brien-Fleming approach with one scheduled
interim analysis, hypothesis testing would be conducted
at an interim significance level of a =0 . 0 0 8 .I fs i g n i f i -
cance is found in favour of the test treatment, the study
m a yb es t o p p e dw i t hs u f f i c i e n t statistical evidence of
efficacy. If the level of significance is not reached at the
interim analysis, the study continues to normal comple-
tion at which time the hypothesis testing is conducted
at a significance level of a = 0.042. This stagewise pro-
cedure will have an overall significance of a = 0.05.
If for any reason no confirmative interim analysis will
be performed, the final significance level will be 5%.
Dose Escalation Scheme
The dose-escalation part of this study was designed to
enroll successive cohorts of 8 patients, each to be
started on a fixed dose of carbon ion therapy. The start-
ing dose was specified as 10 × 3 Gy E for the first
cohort. Planned dose level for subsequent cohorts were
11 × 3 Gy E, 12 × 3 Gy E, 13 × 3 Gy E, 14 × 3 Gy E,
15 × 3 Gy E and 16 × 3 Gy E.
Dose escalation was to be stopped when the maxi-
mum tolerated dose (MTD) was reached. MTD was
defined as one dose level below that at which dose limit-
ing toxicities (DLT) was observed in one-third or more
of the patients meaning that at least 3 of the 8 patients
in one dose cohort experienced a DLT. If maximum 2
DLTs were observed at one dose level, the next higher
dose level will be evaluated. The maximum tolerated
dose corresponds to the recommended dose for the fol-
lowing phase II part of this trial.
Toxicities were graded using the NCI Common Toxi-
city Criteria Version 4.0. DLT was defined as any treat-
ment-related event qualifying as NCI grade 4.
Ethics, informed consent and safety
A positive Ethics Vote was obtained by the Local Ethics
Committee of the medical Faculty at the University of
Heidelberg, Germany.
B e f o r es t u d yr e c r u i t m e n t ,ap o s i t i v ev o t eo ft h eB u n -
desamt für Strahlenschutz (BfS) is necessary.
Treatment at tumor progression
After completion of study treatment not adjuvant treat-
ment is conducted as part of this protocol. Further
treatments may be initiated as needed clinically.
For tumor progression, treatment alternatives will be
evaluated and discussed in the interdisciplinary setting
considering options of neurosurgical resection, systemic
treatment such as chemotherapy, a second course of
radiation therapy, or other.
Discussion
Treatment of recurrent gliomas still remains an interdis-
ciplinary challenge. Re-irradiation using high-precision
photon techniques has been established as a standard
treatment in this clinical situation for a subgroup of
patients: Several different fractionation schemes are
applied in this setting, including hypofractionated regi-
mens or radiosurgery, however, in our institution, Frac-
tionated Stereotactic Radiotherapy (FSRT) with an
attempted total dose of 36 Gy in 2 Gy single fractions is
considered standard treatment [18-23]. Still outcome of
these patients is not satisfactory and novel treatment
appraoches are required.
With heavy charged particle beams such as carbon
ions, the physical benefits of an ion beam in conjunction
with the higher relative biological effectiveness (RBE) can
be exploited for the treatment of different tumor entities.
For several indications, superior clinical results as com-
pared to photon radiotherapy have been shown [24]. Pre-
clinical studies have shown the RBE to be between 3 and
5 for high-grade gliomas, therefore demonstrating that
carbon ions are a promising treatment alternative for
patients with recurrent gliomas [8,25].
Early clincial data on carbon ion radiotherapy in pri-
mary high-grade brain tumors have shown overall safety
even with extensive dose escalation with promising
results; however, few patients had been included into
this study, and therefore validation in a larger patients
collective is warranted [26].
Until now, no patients have been treated with carbon
ion radiotherapy for recurrent gliomas. Based on the
preclinical data as well as the clinical experience so far,
this concept should be evaluated.
Therefore, the present CINDERELLA trial evaluates
carbon ion radiotherapy performed as re-irradiation in
patients with recurrent gliomas compared to FSRT with
standard dosing. In a first Phase I part of the study, a
dose escalation will be performed to determine the opti-
mal dose of carbon ion radiotherapy that can be pre-
scribed in this clinical setting. Thereafter, in the Phase
II part of the trial, patients will be randomized between
carbon ion radiotherapy and FSRT.
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